11 results on '"Yamamoto, Yoshiya"'
Search Results
2. Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
- Author
-
Kawagishi, Naoki, Suda, Goki, Yamamoto, Yoshiya, Baba, Masaru, Furuya, Ken, Maehara, Osamu, Ohnishi, Shunsuke, Yoshida, Sonoe, Fu, Qingjie, Yang, Zijian, Hosoda, Shunichi, Tokuchi, Yoshimasa, Kitagataya, Takashi, Ohara, Masatsugu, Suzuki, Kazuharu, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Ogawa, Koji, and Sakamoto, Naoya
- Subjects
ANGIOPOIETIN-2 ,HEPATITIS C ,HEPATOCELLULAR carcinoma ,HEPATIC fibrosis ,REGRESSION analysis - Abstract
Progressive liver fibrosis after anti-HCV treatment is a risk factor for HCC. Angiopoietin-2 (Ang2) is associated with non-regression of liver fibrosis after direct-acting antiviral (DAA). This study evaluated the predictive value of serum Ang2 levels for HCC occurrence or recurrence after DAA administration. In this retrospective study, 310 HCV-infected patients treated with DAAs in 2014–2020 were screened and evaluated for HCC occurrence or recurrence every three–six months. Multivariate Cox regression analysis revealed that age ≥ 75 years (HR: 2.92, 95% CI: 1.34–6.33; p = 0.007) and baseline Ang2 level ≥ 464 pg/mL (HR: 2.75, 95% CI: 1.18–6.37; p = 0.019) were significantly associated with HCC occurrence after DAA therapy. A high or low risk of HCC after DAA therapy could be distinguished by the combination of age and baseline Ang2 level. The cumulative incidences of de-novo HCC at two and four years were 0.8% and 3.8% in the low-risk group and 22.6% and 27.1% in the high-risk group, respectively. Baseline Ang2 level ≥ 402 pg/mL was significantly associated with HCC recurrence in patients who achieved sustained virological response with DAAs (HR: 3.68). In conclusion, serum Ang2 levels can predict HCC occurrence and recurrence after successful HCV eradication by DAAs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.
- Author
-
Nakai, Masato, Yamamoto, Yoshiya, Baba, Masaru, Suda, Goki, Kubo, Akinori, Tokuchi, Yoshimasa, Kitagataya, Takashi, Yamada, Ren, Shigesawa, Taku, Suzuki, Kazuharu, Nakamura, Akihisa, Sho, Takuya, Morikawa, Kenichi, Ogawa, Koji, Furuya, Ken, and Sakamoto, Naoya
- Subjects
- *
HEPATITIS C virus , *HEPATOCELLULAR carcinoma , *LIVER , *ELASTOGRAPHY , *MULTIVARIATE analysis - Abstract
Liver stiffness measurement (LSM) is a useful tool for assessing advanced liver fibrosis, an important risk factor for hepatocellular carcinoma (HCC) following hepatitis C (HCV) eradication. This study aimed to clarify the non-invasive factors associated with HCC following sustained virological response (SVR) and to identify the low-risk group. 567 patients without history of HCC who achieved SVR at 24 weeks (SVR24) after IFN-free treatment were retrospectively analyzed. The cumulative incidence of HCC and the risk factors were examined using pre-treatment and SVR24 data. The median observation period was 50.2 months. Thirty cases of HCC were observed, and the 4-year cumulative incidence of HCC was 5.9%. In multivariate analysis, significant pre-treatment factors were age ≥ 71 years (hazard ratio [HR]: 3.402) and LSM ≥ 9.2 kPa (HR: 6.328); SVR24 factors were age ≥ 71 years (HR: 2.689) and LSM ≥ 8.4 kPa (HR: 6.642). In cases with age < 71 years and LSM < 8.4 kPa at the time of SVR24, the 4-year cumulative incidence of HCC was as low as 1.1%. Both pre-treatment LSM (≥ 9.2 kPa) and SVR24 LSM (≥ 8.4 kPa) and age (≥ 71 years) are useful in predicting the risk of HCC after SVR with IFN-free treatment. Identification of low-risk individuals may improve the efficiency of follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
- Author
-
Suda, Goki, Hasebe, Chitomi, Abe, Masami, Kurosaki, Masayuki, Itakura, Jun, Izumi, Namiki, Uchida, Yoshihito, Mochida, Satoshi, Haga, Hiroaki, Ueno, Yoshiyuki, Abe, Kazumichi, Takahashi, Atsushi, Ohira, Hiromasa, Tsukuda, Yoko, Furuya, Ken, Baba, Masaru, Yamamoto, Yoshiya, Kobayashi, Tomoe, Inoue, Jun, and Terasita, Katsumi
- Subjects
HEMODIALYSIS patients ,HEPATITIS C virus ,VIRUS diseases ,GENOTYPES ,THERAPEUTICS - Abstract
Background: Until recently, interferon-free anti-hepatitis C virus (HCV) therapy for genotype 2 (GT2) HCV-infected hemodialysis patients was an unfulfilled medical need. Recent clinical trials of glecaprevir and pibrentasvir (G/P) for hemodialysis patients showed high efficacy and safety; however, the number of GT2 HCV-infected patients, especially Asian patients, was limited and most of them were treated with a 12-week regimen. In this prospective multicenter study, we aimed to investigate the efficacy and safety of G/P in Japanese hemodialysis patients with GT2 HCV infection.Methods: Twenty-seven Japanese hemodialysis patients with GT2 HCV infection who were started on with 8- or 12-week G/P regimen between November 2017 and June 2018 were included and followed up for around 12 weeks after treatment completion.Results: Among the 27 included patients, 13 non-liver cirrhosis (LC) and direct-acting antivirals (DAAs)-naïve patients were treated with 8 weeks of G/P and 14 patients with LC (n = 13) or history of failure of DAAs (n = 1) were treated with a 12-week regimen. The overall sustained virological response at 12 weeks after treatment completion (SVR 12) was 96.3% (26/27). All patients with 8 weeks of treatment achieved SVR12. Two patients discontinued the therapy at 2 and 11 weeks after treatment initiation. The patient who discontinued at 2 weeks due to pruritus alone failed to respond to G/P. No patients experienced lethal adverse events during the therapy, and the most common adverse event was pruritus.Conclusions: An 8- or 12-week G/P regimen is highly effective and safe in GT2 HCV-infected hemodialysis patients. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
5. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
- Author
-
Suda, Goki, Kurosaki, Masayuki, Itakura, Jun, Izumi, Namiki, Uchida, Yoshihito, Mochida, Satoshi, Hasebe, Chitomi, Abe, Masami, Haga, Hiroaki, Ueno, Yoshiyuki, Masakane, Ikuto, Abe, Kazumichi, Takahashi, Atsushi, Ohira, Hiromasa, Furuya, Ken, Baba, Masaru, Yamamoto, Yoshiya, Kobayashi, Tomoe, Kawakami, Atsuhiko, and Kumagai, Kenichi
- Subjects
HEPATITIS C virus ,HEPATITIS C ,CLINICAL trial registries ,HEMODIALYSIS patients ,VIRUS diseases ,GENOTYPES - Abstract
Background: The prevalence of hepatitis C virus (HCV) infection in hemodialysis patients is high and results in a poor prognosis. Thus, safer and more effective treatment regimens are required. In this prospective multicenter study, we investigated the efficacy and safety of the novel HCV-NS5A-inhibitor, elbasvir, and protease inhibitor, grazoprevir in Japanese hemodialysis patients with genotype 1b HCV infection.Methods: This study is registered at the UMIN Clinical Trials Registry as UMIN00002578. A total of 23 Japanese dialysis patients with genotype 1b HCV infection who were treated with elbasvir and grazoprevir between January 2017 and March 2018 and followed for more than 12 weeks after treatment completion were included. We evaluated the sustained virologic response at 12 weeks after treatment completion (SVR12) and safety during treatment.Results: Of the 23 patients, 7 had advanced liver fibrosis and 2 had a signature resistance-associated variant of NS5A (NS5A RAVs)-L31M/V or Y93H at baseline. All patients completed therapy, and 96.7% (22/23) of the patients achieved SVR12. All patients with advanced liver fibrosis and signature NS5A RAVs at baseline achieved SVR12 with a high safety profile. No patient experienced lethal or severe adverse events during therapy, and the most common adverse event was anemia. One patient, who was a non-responder to this therapy, had a history of failure with daclatasvir and asunaprevir therapies and had NS5A RAVs of A92K at baseline, but not signature NS5A RAVs.Conclusions: Grazoprevir and elbasvir combination is highly effective and safe for hemodialysis patients with genotype 1b HCV infection. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
- Author
-
Sho, Takuya, Suda, Goki, Nagasaka, Atsushi, Yamamoto, Yoshiya, Furuya, Ken, Kumagai, Kenichi, Uebayashi, Minoru, Terashita, Katsumi, Kobayashi, Tomoe, Tsunematsu, Izumi, Onodera, Manabu, Meguro, Takashi, Kimura, Megumi, Ito, Jun, Umemura, Machiko, Izumi, Takaaki, Kawagishi, Naoki, Ohara, Masatsugu, Ono, Yuji, and Nakai, Masato
- Subjects
HEPATITIS C ,KIDNEY diseases ,SOFOSBUVIR ,RIBAVIRIN ,MULTIVARIATE analysis ,ANALYSIS of variance - Abstract
Aim: The safety and efficacy of sofosbuvir (SOF) and ribavirin (RBV) have not been well clarified in patients with renal dysfunction because clinical trials have not included such patients. We evaluated the safety and efficacy of SOF and RBV for genotype 2 hepatitis C virus (HCV)‐infected patients with renal dysfunction. Methods: The study included genotype 2 HCV‐infected patients who received SOF and RBV between July 2014 and May 2017. The sustained virologic response (SVR) after the treatment and safety during the therapy were evaluated according to renal function. Results: A total of 231 patients were included in this study. The median age was 62 years old, and 45.9% (106/231) were men. Of the 231 patients, 191 (82.8%) and 40 (17.2%) were classified as having chronic kidney disease (CKD) stages G1/2 and G3, respectively. The overall SVR rate was 97% (224/231). The SVR rates in patients with CKD stages G1, 2, G3a, and G3b were 98.1%, 98.6%, 87.9%, and 100%, respectively, and this therapy was tolerated. Multivariate analysis indicated that renal dysfunction was significantly associated with a non‐SVR (odds ratio, 6.963; 95% confidence interval, 1.494–32.41; P = 0.013). The patients with renal dysfunction were older, had advanced liver fibrosis, lower baseline platelet and hemoglobin levels, and a higher rate of RBV dose reduction. Conclusions: Sofosbuvir and RBV therapy is highly effective and safe for genotype 2 HCV‐infected Japanese patients. However, attention should be paid to baseline renal function when SOF‐ and RBV‐containing regimens are used for patients with renal dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study.
- Author
-
Suda, Goki, Ito, Jun, Nagasaka, Atsushi, Yamamoto, Yoshiya, Furuya, Ken, Okamoto, Munenori, Terashita, Katsumi, Kobayashi, Tomoe, Tsunematsu, Izumi, Yoshida, Junichi, Meguro, Takashi, Ohara, Masatsugu, Kawagishi, Naoki, Kimura, Megumi, Umemura, Machiko, Izumi, Takaaki, Tsukuda, Yoko, Nakai, Masato, Sho, Takuya, and Natsuizaka, Mitsuteru
- Subjects
FLUVASTATIN ,RIBAVIRIN ,THERAPEUTIC use of protease inhibitors ,HEPATITIS C virus ,HEPATITIS C treatment ,THERAPEUTICS ,PATIENTS - Abstract
Background: The Japan Society of Hepatology guidelines indicate that hepatitis C virus (HCV) protease inhibitor combination therapy with simeprevir (SMV), pegylated‐interferon (Peg‐IFN), and ribavirin (RBV) is a therapeutic option for patients who fail to respond to a direct direct‐acting antiviral‐containing regimen. However, treatment outcomes have room for improvement. Fluvastatin (FLV) add‐on treatment in Peg‐IFN and RBV combination therapy for HCV‐infected patients significantly improved the sustained virologic response (SVR), but the add‐on effect of FLV on SMV combination therapy is not well understood. Methods: This was a prospective, randomized, multicenter study in which a total of 61 HCV genotype 1b‐infected patients were recruited and 60 eligible patients were randomly allocated to two groups that received 12 weeks of SMV/Peg‐IFN/RBV followed by 12 weeks of Peg‐IFN/RBV with or without 24 weeks of FLV. The SVR rate and adverse events were compared between the two groups. Results: Thirty‐one patients were allocated to the FLV add‐on group and 29 patients were allocated to the control group. Baseline clinical factors, including median age, baseline platelet count, alanine aminotransferase level, HCV RNA titer, Fibrosis‐4 index, and rate of IL28B minor genotype, were all similar between the two groups. The rapid virologic response, end‐of‐treatment response rates, SVR rates at 24 weeks after treatment, and safety profiles were also similar between the two groups. Conclusions: This prospective, randomized, multicenter study indicated that FLV had no add‐on effect when given with SMV/Peg‐IFN/RBV combination therapy for genotype 1b HCV‐infected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.
- Author
-
Tsutsumi, Yutaka, Nakayama, Chie, Kamada, Koki, Kikuchi, Ryo, Kudo, Daiki, Ito, Shinichi, Matsuoka, Satomi, Shiratori, Souichi, Yamamoto, Yoshiya, Naruse, Hirohito, and Teshima, Takanori
- Subjects
HEPATITIS C treatment ,ANTIVIRAL agents ,HEPATITIS C virus ,DIFFUSE large B-cell lymphomas ,TREATMENT effectiveness ,THERAPEUTICS ,ANTINEOPLASTIC agents ,B cell lymphoma ,CLINICAL trials ,COMPARATIVE studies ,DOXORUBICIN ,HEPATITIS C ,HEPATITIS viruses ,RESEARCH methodology ,MEDICAL cooperation ,MONOCLONAL antibodies ,PREDNISONE ,PROGNOSIS ,RESEARCH ,RNA ,SURVIVAL ,VINCRISTINE ,PILOT projects ,EVALUATION research ,CYCLOPHOSPHAMIDE - Abstract
The purpose of this study is to study the usefulness of post-remission antiviral therapy in cases of HCV-RNA-positive diffuse large-cell lymphoma. Antiviral therapy against HCV was performed after remission using CHOP or CHOP-like chemotherapy in combination with rituximab in five successive cases of HCV-RNA-positive diffuse large-cell lymphoma. The control groups consisted of a group of HCV-RNA-positive diffuse large-cell lymphoma cases prior to this trial (control 1), and a group of cases that tested negative for HIV, HCV, and HBV (control 2). All the cases were in remission at the time of initial treatment. There were no significant differences between the three groups in terms of age, sex, treatment, stage, or International Prognosis Index (IPI). When HCV antiviral therapy was performed after treatment for diffuse large-cell lymphoma, we observed no recurrence or deaths, and the 2-year overall survival and progression-free survival rates were significantly greater than those in the control 1 group (P = 0.0246). It is possible that a better prognosis can be achieved by performing HCV antiviral therapy after achieving remission in cases of HCV-RNA-positive diffuse large-cell lymphoma through the use of R-CHOP or similar treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.
- Author
-
Suda, Goki, Nagasaka, Atsushi, Yamamoto, Yoshiya, Furuya, Ken, Kumagai, Kenichi, Kudo, Mineo, Terashita, Katsumi, Kobayashi, Tomoe, Tsunematsu, Izumi, Yoshida, Junichi, Meguro, Takashi, Kimura, Megumi, Ito, Jun, Umemura, Machiko, Izumi, Takaaki, Tsunematsu, Seiji, Sato, Fumiyuki, Tsukuda, Yoko, Nakai, Masato, and Sho, Takuya
- Subjects
HEPATITIS C treatment ,HEPATITIS C ,FLAVIVIRAL diseases ,KIDNEY diseases ,SOFOSBUVIR ,ANTIVIRAL agents - Abstract
Aim Hepatitis C virus (HCV) infection is a risk factor for end-stage renal disease, renal graft failure, and hemodialysis patient mortality. However, the efficacy of direct-acting antiviral therapy for HCV-infected patients with renal impairment is unclear. Additionally, the promising NS5B inhibitor sofosbuvir has not been recommended for patients with severe renal impairment. In this prospective, multicenter study, we evaluated the efficacy and safety of daclatasvir and asunaprevir combination therapy, with a focus on patients with renal impairment. Methods The study included 322 genotype 1 HCV-infected patients who received daclatasvir and asunaprevir combination therapy. The safety and sustained virological response was examined at 12 weeks after the end of treatment and safety was evaluated according to renal function. Results Of 322 patients, 5% (16/322) and 2.5% (8/322) had chronic kidney disease stage G3b (estimated glomerular filtration rate [eGFR], 30-44 mL/min/1.73 m
2 ) and stage G4/5 (eGFR, 15-29/<15 mL/min/1.73 m2 ), respectively. Baseline presence of the NS5A resistance-associated variant, previous simeprevir treatment, and HCV RNA titers, which were predictors of a sustained viral response, were similar between patients with eGFR <45 mL/min/1.73 m2 and eGFR >45 mL/min/1.73 m2 . Notably, the 12-week sustained viral response rate was comparable in patients with eGFR <45 mL/min/1.73 m2 (100%, 24/24) and those with eGFR >45 mL/min/1.73 m2 (88.9%, 265/298; P = 0.07). Treatment discontinuation rates and adverse events, including alanine aminotransferase elevation, anemia, and renal disorders, were similar between the two groups. Conclusion Daclatasvir and asunaprevir combination therapy for patients with renal dysfunction was highly effective and safe. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
10. Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
- Author
-
Ito, Jun, Suda, Goki, Yamamoto, Yoshiya, Nagasaka, Atsushi, Furuya, Ken, Kumagai, Kenichi, Kikuchi, Hideaki, Miyagishima, Takuto, Kobayashi, Tomoe, Kimura, Megumi, Yamasaki, Kazushi, Umemura, Machiko, Izumi, Takaaki, Tsunematsu, Seiji, Sato, Fumiyuki, Tsukuda, Yoko, Terashita, Katsumi, Nakai, Masato, Sho, Takuya, and Natsuizaka, Mitsuteru
- Subjects
HEPATITIS C ,DISEASE prevalence ,SOFOSBUVIR ,DRUG resistance in microorganisms ,ANTIVIRAL agents ,DRUG activation ,PATIENTS - Abstract
Aim Sofosbuvir (SOF), a nucleotide analog pro-drug, targets hepatitis C virus (HCV) NS5B polymerase and shows potential for treating HCV infection, given its high efficacy and good barrier to resistance. However, in addition to the rare resistant-associated variant (RAV) of non-structural protein NS5B S282T, several new potential RAVs of SOF have been reported, especially related to HCV genotype 1b. However, the prevalence and characteristics of these RAVs have not been clarified. Methods We analyzed the prevalence of variants in the NS3/NS5A/NS5B regions in 96 patients treated with simeprevir (SMV) combination therapy, and the prevalence of RAVs in patients showing treatment failure was determined by direct- or deep-sequencing methods. Associations between these potential RAVs and clinical factors were also analyzed. Results Prevalence of NS5B RAV C316N was high (46.9%, 45/96), whereas that of NS5B L159F was relatively low (1.04%, 1/96); however, deep sequencing showed that 30.0% of patients with C316N also had NS5B RAV L159F. Additionally, there was no significant relationship between the existence of potential NS5B and NS5A or NS3 RAVs. However, the presence of NS5B C316N was significantly associated with an HCV core amino acid 91 substitution. No significant difference was detected between each RAV and sustained virological response in simeprevir combination therapy. Conclusion We provide clear evidence of the high prevalence of two potential naturally occurring NS5B RAVs (C316N and L159F) in Japan. It may be important to pay particular attention to these new potential RAVs, especially when using SOF-based therapy in patients with RAVs due to previous direct-acting antiviral therapy failure. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions.
- Author
-
Suda, Goki, Yamamoto, Yoshiya, Nagasaka, Astushi, Furuya, Ken, Kudo, Mineo, Chuganji, Yoshimichi, Tsukuda, Yoko, Tsunematsu, Seiji, Sato, Fumiyuki, Terasita, Katsumi, Nakai, Masato, Horimoto, Hiromasa, Sho, Takuya, Natsuizaka, Mitsuteru, Ogawa, Kouji, Ohnishi, Shunsuke, Chuma, Makoto, Fujita, Yasuyuki, Abe, Riichiro, and Taniguchi, Miki
- Subjects
- *
GRANULYSIN , *TELAPREVIR , *BLOOD serum analysis , *DRUG-induced abnormalities , *SKIN diseases - Abstract
Aim Telaprevir-based therapy for chronic hepatitis C patients is effective; however, the high prevalence of dermatological reactions is an outstanding issue. The mechanism and characteristics of such adverse reactions are unclear; moreover, predictive factors remain unknown. Granulysin was recently reported to be upregulated in the blisters of patients with Stevens- Johnson syndrome ( SJS). Therefore, we investigated the risk factors for severe telaprevir-induced dermatological reactions as well as the association between serum granulysin levels and the severity of such reactions. Methods A total of 89 patients who received telaprevir-based therapy and had complete clinical information were analyzed. We analyzed the associations between dermatological reactions and clinical factors. Next, we investigated the time-dependent changes in serum granulysin levels in five and 14 patients with grade 3 and non-grade 3 dermatological reactions, respectively. Results Of the 89 patients, 57 patients had dermatological reactions, including nine patients with grade 3. Univariate analysis revealed that grade 3 dermatological reactions were significantly associated with male sex. Moreover, serum granulysin levels were significantly associated with the severity of dermatological reactions. Three patients with grade 3 dermatological reaction had severe systemic manifestations including SJS, drug-induced hypersensitivity syndrome, and systemic lymphoid swelling and high-grade fever; all were hospitalized. Importantly, among the three patients, two patients' serum granulysin levels exceeded 8 ng/mL at onset and symptoms deteriorated within 6 days. Conclusion Male patients are at high risk for severe telaprevir-induced dermatological reactions. Moreover, serum granulysin levels are significantly associated with the severity of dermatological reactions and may be a predictive factor in patients treated with telaprevir-based therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.